World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
54527
World Ranking
6143
National Ranking
3284

Daniel J. Wallace publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel J. Wallace sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 609 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel J. Wallace D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel J. Wallace sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 107 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel J. Wallace is affiliated with Cedars-Sinai Medical Center in the United States. Their research primarily focuses on Medicine, with significant work in Rheumatology, Immunology, Pathology and Forensic Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

The scientist's main topics of study include Systemic Lupus Erythematosus Research, Atherosclerosis and Cardiovascular Diseases, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, Systemic Sclerosis and Related Diseases, Chronic Lymphocytic Leukemia Research, and Cytokine Signaling Pathways and Interactions.

Recent published papers include:

  • Macrophage fumarate hydratase restrains mtRNA-mediated interferon production, 2023, Nature
  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I), 2023, The Lancet
  • Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort, 2021, Lara D. Veeken
  • Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, 2021, Annals of the Rheumatic Diseases
  • Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells, 2022, Nature Communications

Frequent co-authors include Rosalind Ramsey-Goldman, Kenneth Kalunian, Cynthia Aranow, Ann E. Clarke, and Diane L. Kamen. These collaborative partnerships have contributed to numerous studies across the related fields.

The scientist's work is frequently published in venues such as Annals of the Rheumatic Diseases, UNC Libraries, Lupus Science & Medicine, Arthritis & Rheumatology, and Arthritis Care & Research.

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks

  • The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

    Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

    Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace

  • Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

    Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan

  • Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

    Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim

  • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

    Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu

  • A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

    Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei

  • Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.

    M Linker-Israeli;R J Deans;D J Wallace;J Prehn

  • Dubois' Lupus Erythematosus

    Daniel J. Wallace

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

    Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse

  • Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N Bruce;Aidan G O'Keeffe;Vernon Farewell;John G Hanly

  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

    Daniel J Wallace;Richard A Furie;Yoshiya Tanaka;Kenneth C Kalunian

  • Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

    Maureen McMahon;Jennifer Grossman;John FitzGerald;Erika Dahlin-Lee

  • Lupus erythematosus in the 1980s: a survey of 570 patients.

    Moshe Pistiner;Daniel J. Wallace;Sharon Nessim;Allan L. Metzger

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

    Daniel J Wallace;Kenneth Kalunian;Michelle A Petri;Vibeke Strand

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

Frequent Co-Authors

Michael H. Weisman
Michael H. Weisman Cedars-Sinai Medical Center
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Joan T. Merrill
Joan T. Merrill Oklahoma Medical Research Foundation
Kenneth C. Kalunian
Kenneth C. Kalunian University of California, San Diego
Murray B. Urowitz
Murray B. Urowitz University of Toronto
Caroline Gordon
Caroline Gordon University of Birmingham
Ann E. Clarke
Ann E. Clarke University of Calgary
David A. Isenberg
David A. Isenberg University College London
Susan Manzi
Susan Manzi Allegheny Health Network

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical education, there is growing interest in allied healthcare degrees that offer flexible, online, and accelerated options. If you’re seeking advanced nursing qualifications, consider exploring accelerated dnp programs online and dnp online programs. These options can enable you to earn a Doctor of Nursing Practice degree in less time, supporting a quicker pathway to leadership or specialized roles.

For those aiming to enter the workforce sooner, there are accelerated lpn program tracks that make it possible to become a Licensed Practical Nurse quickly and flexibly. If mental health is your focus, you may want to look into the fastest psych np program options, letting you earn a specialized MSN and step into critical psychiatric nurse practitioner roles.

These online degrees can be appealing for working professionals, career changers, or anyone wanting to advance rapidly. Program length, admission requirements, and career prospects should be considered carefully before choosing a pathway.

Best Scientists Citing Daniel J. Wallace

Trending Scientists

Recently Published Articles